Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30881298 | 1.00 | CA12 (0.47) | CA12CA9ALDH1A1MEN1KMT2A | |
| Alcohol SCHEMBL9054340 | 0.95 | ALDH1A1 (0.45) | CA12CA9ALDH1A1KMT2ACHRM2 | |
| SCHEMBL4711840 | 0.86 | CA12 (0.44) | CA12CA9ALDH1A1MEN1KMT2A | |
| SCHEMBL30280109 | 0.86 | CA12 (0.44) | CA12CA9ALDH1A1MEN1KMT2A | |
| SCHEMBL30444643 | 0.84 | CA12 (0.46) | CA12CA9ALDH1A1MEN1KMT2A | |
| SCHEMBL30881309 | 0.82 | GLS (0.49) | CA12CA9GABRA1GABRG2GABRB3 | |
| SCHEMBL9055216 | 0.82 | GLS (0.49) | CA12CA9GABRA1GABRG2GABRB3 | |
| SCHEMBL17942059 | 0.81 | CA12 (0.56) | CA12CA9ALDH1A1MEN1KMT2A | |
| SCHEMBL22939448 | 0.80 | CA12 (0.48) | CA12CA9ALDH1A1GLSCHRM2 | |
| SCHEMBL9827776 | 0.80 | GLS (0.50) | MEN1KMT2AGLSCHRM2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2321319-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010011959-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011959-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-0472181-B1 | 5-Amine substituted adenosine analogs as immunosuppressants | MERRELL PHARMA INC (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5416076-A | S-adenosyl methionine decarboxylase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-05-16 | — | — | US | disclosed |
| US-5308837-A | 5'-amine substituted adenosine analogs as immunosuppressants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-05-03 | — | — | US | disclosed |
| EP-0472181-A2 | 5-Amine substituted adenosine analogs as immunosuppressants | MERRELL PHARMACEUTICALS INC. (US) | 1992-02-26 | — | — | EP | disclosed |
| EP-0358536-A2 | Novel S-adenosyl methionine decarboxylase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1990-03-14 | — | — | EP | disclosed |
| EP-0351475-A1 | S-Adenosylmethionine decarboxylase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA12 4309/4885CA9 3805/4885ALDH1A1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.